Merck & Co (MRK)

Common Stock

Sell: $87.05|Buy: $87.66|Change: 0.43 (-0.49%)

Not yet a customer?

Low cost dealing from £1.50

Choose from our range of SIPP, ISA and Dealing accounts

Open

$87.56

Previous close

$87.61

Trade high

$88.105

Volume

7,687,450

Year high

$107.362

Year low

$73.31

Dividend yield

3.7%

Market capitalisation

$217.76 bn

P/E ratio

13.50

ISIN

US58933Y1055

This share can be held in a Dealing account Stocks and shares ISA Lifetime ISA JISA SIPP

Share price

Dividends

	Previous	Latest
Record date	16/06/2025	15/09/2025
Ex-dividend date	16/06/2025	15/09/2025
Payment date	08/07/2025	07/10/2025
Amount	$0.81	$0.81

Performance 23/10/2025

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann

	Total return (%)
Merck & Co	- 0.49
More...

Company profile

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographicalperspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).

Sector

Healthcare

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.